Approval · Notice of Compliance 10004 · 2009
ENABLEX: Notice of Compliance 10004
Issued January 22, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10004
- Date
- January 22, 2009
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in site of manufacture of the drug product
- Therapeutic class
- Muscarinic m3 selective receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENABLEX | Not yet assigned | — |
Medicinal ingredients
- DARIFENACIN HYDROBROMIDE 15 MG per TAB